Division Head and Professor of Pharmacology and Toxicology Karen Vasquez, Ph.D. appeared on BBC World Service's Science in Action to talk about Z-DNA. Dr. Vasquez's research focuses on DNA damage and repair, genomic instability, gene targeting, DNA structure and cancer therapeutics.
Combining mobile health technology, or mHealth, and community outreach to improve the health outcomes of people experiencing homelessness is the target of a new study led by Division of Health Outcomes Associate Professor Leticia Moczygemba, Pharm.D., Ph.D., thanks to a five-year research grant from the U.S. Department of Health and Human Services Agency for Healthcare Research and Quality.
Three researchers from the College of Pharmacy won an award from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. Leticia R. Moczygemba, Pharm.D., Ph.D., Carolyn M. Brown, Ph.D. and Michael Johnsrud, Ph.D., R.Ph. were awarded $5,000 from the PhRMA Foundation for their proposal to advance racial and ethnic representation in value assessments.
Associate Dean for Research and Graduate Studies John H. Richburg, Ph.D. received notice from the National Institutes of Health (NIH) awarding him a research grant for a five-year term. The NIH’s grant award for Dr. Richburg’s research totals $2,694,316.
Pharmacology and Toxicology Professor Andrea C. Gore, Ph.D. recently received an impressive five-year RO1 grant from the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes for Health (NIH), for research to determine how PCBs cause dysfunctions in reproductive physiology and behavior.
College of Pharmacy Professor Karen M. Vasquez, Ph.D. recently collaborated on a research paper exploring the mechanisms involved in DNA structure-induced genetic instability in human disease. “Mechanisms of genetic instability caused by (CGG)n repeats in an experimental mammalian system” recently published in Nature, and includes co-authors Artem V. Kononenko, Thomas Ebersole, and Sergei M. Mirkin from Tufts University.